Govt to set up 49 cancer centres in 3 yrs

With cancer cases on the rise in the country, the government plans to set up 49 cancer centres in the next three years. The centres will be in addition to 31 already functioning and upgraded since 2014-15, when the government floated the scheme.

The health ministry has drawn up a detailed project plan which will be reviewed by the Prime Minister's Office (PMO) at a high-level meeting on Monday. According to the proposal, reviewed by TOI, the ministry has estimated a cost of around Rs 3,495 crore to implement the scheme over the next three years. The cancer centres will be set up in a phased manner under the existing National Programme for Prevention and Control of Cancer, Diabetes, Cardiovascular Diseases and Stroke.

Non-communicable diseases, especially cancer, are increasing at an alarming rate. However, there is a serious dearth of facilities, mainly at the district level. The idea is to make treatment options available across India so that patients do not necessarily have to travel to Delhi and Mumbai, which often leads to additional costs like accommodation, travelling etc," an official said.

In India, over 10 lakh new cases of cancer are diagnosed every year. However, due to late diagnosis, over 7 lakh people die from the disease each year. Projections by Indian Council of Medical Research (ICMR) show that India is likely to have over 17.3 lakh new cases of cancer and over 8.8 lakh deaths due to the disease by 2020.

Apart from setting up cancer centres — which include construction or upgrade of existing facilities like district hospitals, regional cancer centres and government medical colleges — the government's programme will also provide support for high-end equipment and advanced technology for cancer treatment, the official said.
For instance, there are only 600 radiotherapy machines in the country against a requirement of about 1,200 machines, as per estimates by the WHO. Under the scheme, there will be an increase of around 175 radiotherapy machines in India by the end of 2020. The proposal also entails the creation of more facilities for oncology, onco-surgery, chemotherapy and palliative care for diagnosis, treatment and rehabilitation of cancer. "These institutes will also mentor all cancer-related activities, including research and development, in their respective areas," the official said.

While the 49 new cancer centres will be initially set up under two categories — state cancer institutes and tertiary care cancer centres (TCCCs) in a phased manner — they will be responsible for building capacities of other institutions below for prevention, control, diagnosis and treatment.

 Source:http://timesofindia.indiatimes.com/india/govt-to-set-up-49-cancer-centres-in-3-yrs/articleshow/60725429.cms

Comments

Post a Comment

Popular posts from this blog

EMA validates Incyte’s MAA for retifanlimab to treat metastatic squamous cell anal carcinoma

Incyte, global biopharmaceutical company, announced the validation of the Company’s Marketing Authorization Application (MAA) for retifanlimab, an intravenous PD-1 inhibitor, as a potential treatment for adult patients with locally advanced or metastatic squamous cell anal carcinoma (SCAC) who have progressed on, or who are intolerant of, platinum-based chemotherapy. The European Medicines Agency’s (EMA) validation of the MAA confirms that the submission is sufficiently complete to begin the formal review process. “While the incidence of SCAC is increasing in Europe, treatment options for advanced disease are limited in their effectiveness, and there are no approved options once patients have progressed on standard therapy,” said Lance Leopold, M.D., Group vice president, Immuno-Oncology Clinical Development, Incyte. “The EMA validation of the MAA for retifanlimab – which follows the recent US Food & Drug Administration acceptance of our Biologics License Application for Priority R...
Read more

Tumour-targeting drug paves way for bone cancer treatment

 The treatment of osteosarcoma, the most common tumour of bone, is challenging, but a new study is offering hope to the patients with this disease. The study led by The University of  Texas MD Anderson Cancer Centre  found that a drug, known as bone metastasis-targeting peptidomimetic (BMTP-11), has potential as a new therapeutic strategy for this devastating illness. Results from the preclinical study looked at BMTP-11 alone and in combination with the chemotherapy agent gemcitabine. Although osteosarcoma is a relatively rare cancer, it is a leading disease-related cause of death in children and young adults ages 10 to 20. However, over the last 25 years, the five-year survival rate has remained unchanged, and the treatment options for these patients are few. In addition, the side effects of available treatment options often are significant and cumulative, and may cause other health problems and damage to major organs. "What's novel about this treatment is that...
Read more

Merck’s Keytruda plus platinum- and fluoropyrimidine-based chemotherapy receives US FDA nod to treat certain patients with locally advanced/metastatic esophageal or GEJ carcinoma

Merck, known as MSD outside the United States and Canada, announced that the US Food and Drug Administration (FDA) has approved Keytruda, Merck’s anti-PD-1 therapy, for the treatment of patients with locally advanced or metastatic esophageal or gastroesophageal junction (GEJ) (tumors with epicenter 1 to 5 centimeters above the GEJ) carcinoma that is not amenable to surgical resection or definitive chemoradiation in combination with platinum- and fluoropyrimidine-based chemotherapy. The approval is based on results from the phase 3 KEYNOTE-590 trial, which demonstrated significant improvements in overall survival (OS), progression-free survival (PFS) and objective response rate (ORR) for Keytruda plus fluorouracil (FU) and cisplatin versus FU and cisplatin alone, regardless of histology or PD-L1 expression status. For OS and PFS, Keytruda plus FU and cisplatin reduced the risk of death by 27% (HR=0.73 [95% CI, 0.62-0.86]; p<0.0001) and reduced the risk of disease progression or death...
Read more